INTRODUCTION
cancer, pain, ALL
NEPHROBLASTOMA, CHILDHOOD CANCER, CANCER, ACUTE LYMPHOBLASTIC LEUKEMIA, SECONDARY, LYMPHOMA
Vincristine is a chemotherapeutic agent that is frequently used in childhood cancer treatment protocols, such as those for acute lymphoblastic leukemia (ALL), lymphoma, and nephroblastoma.Severe VIPN is estimated to affect up to 30% of patients, but it remains a challenge to predict which patients are at risk.The treatment options for VIPN are limited to pain medication and reducing vincristine dosage.The VINCA trial is a randomized controlled trial (RCT) on the effect of 1‐hour infusion compared with push injection on VIPN in children with cancer. In the first report of the VINCA trial (median follow‐up 9 months), we found no effect of administration duration of vincristine on VIPN. However, in participants receiving concurrent azoles, 1‐hour infusion resulted in less VIPN compared with push injection. In this final follow‐up study (median follow‐up 20 months), we assess the long‐term effect of vincristine administration duration on the development of VIPN. As a secondary objective, we assessed the effect on treatment outcome (follow‐up 3 years).